Paper37985191
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D and 7 others. Cancer Commun (Lond), 2024. Cited by 148 papers, by iCite.
Cite this record
ConductScience Library. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Papers, record 37985191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37985191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Management of locally advanced non-small cell lung cancer: State of the art and future directions.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Neoplasm Staging | |
| Combined Modality Therapy | |
| Prognosis |
Source PubMed
References118
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26275735 | Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. | Lancet | 2015 | https://conductscience.org/library/papers/26275735 | PubMed |
| 2 | 19632716 | Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. | Lancet | 2009 | https://conductscience.org/library/papers/19632716 | PubMed |
| 3 | 37985191 | Management of locally advanced non-small cell lung cancer: State of the art and future directions. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/37985191 | PubMed |
| 4 | 32161398 | Inflammatory microenvironment remodelling by tumour cells after radiotherapy. | Nat Rev Cancer | 2020 | https://conductscience.org/library/papers/32161398 | PubMed |
| 5 | 36720083 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36720083 | PubMed |
| 6 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 7 | 39173098 | Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39173098 | PubMed |
| 8 | 31445730 | Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification. | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/31445730 | PubMed |
| 9 | 28899864 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28899864 | PubMed |
| 10 | 34290408 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. | Nature | 2021 | https://conductscience.org/library/papers/34290408 | PubMed |
| 11 | 16015535 | Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. | Semin Oncol | 2005 | https://conductscience.org/library/papers/16015535 | PubMed |
| 12 | 14662433 | Excisional surgery for cancer cure: therapy at a cost. | Lancet Oncol | 2003 | https://conductscience.org/library/papers/14662433 | PubMed |
| 13 | 28727865 | Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28727865 | PubMed |
| 14 | 34251873 | SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34251873 | PubMed |
| 15 | 31194613 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31194613 | PubMed |
| 16 | 32469385 | Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32469385 | PubMed |
| 17 | 8043059 | A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. | N Engl J Med | 1994 | https://conductscience.org/library/papers/8043059 | PubMed |
| 18 | 37013636 | A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer. | Genome Med | 2023 | https://conductscience.org/library/papers/37013636 | PubMed |
| 19 | 34116229 | Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. | J Thorac Oncol | 2021 | https://conductscience.org/library/papers/34116229 | PubMed |
| 20 | 19861907 | Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. | J Thorac Oncol | 2009 | https://conductscience.org/library/papers/19861907 | PubMed |
Cited by122
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959600 | Shining a Light on the Mechanisms of Drug Resistance to Anti-PD-1 Therapy in Non-small Cell Lung Cancer. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42959600 | PubMed |
| 42919317 | ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42919317 | PubMed |
| 42870959 | Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42870959 | PubMed |
| 42771098 | ProtoSurv: prototype-guided adaptation of computed tomography foundation model for lung-cancer prognosis prediction. | Vis Comput Ind Biomed Art | 2026 | https://conductscience.org/library/papers/42771098 | PubMed |
| 42724680 | Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42724680 | PubMed |
| 42724255 | Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42724255 | PubMed |
| 42723745 | Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42723745 | PubMed |
| 42630367 | Alterations in peripheral blood inflammatory mediators, vascular endothelial growth factor, and serum tumor markers in advanced non-small cell lung cancer patients treated with bevacizumab combined with chemotherapy. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42630367 | PubMed |
| 42591560 | Clinical overall survival prediction and disease characteristics of locally advanced non-small cell lung cancer: an integrated analysis based on the SEER and TCGA databases. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591560 | PubMed |
| 42583196 | Machine learning models predict survival in unresectable stage III non-small cell lung cancer: Surveillance, Epidemiology, and End Results and Chinese cohort study. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42583196 | PubMed |
| 42559326 | Calcium Phosphate Nanoparticle Delivery of siTRIB3 Inhibits EMT and Stemness in NSCLC. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42559326 | PubMed |
| 42524437 | Integrative bulk and single-cell transcriptomic analysis identify an ac4C-related signature in lung adenocarcinoma. | J Cancer | 2026 | https://conductscience.org/library/papers/42524437 | PubMed |
| 42505209 | Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42505209 | PubMed |
| 42453889 | Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42453889 | PubMed |
| 42449581 | Efficacy and Time-Dependent Pattern of Consolidation Immunotherapy in Stage III Non-Small Cell Lung Cancer After Induction Chemoimmunotherapy and Radiotherapy: A Dual-Center Retrospective Cohort Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449581 | PubMed |
| 42366402 | From metabolic to pathologic complete response: case report of Neoadjuvant Lorlatinib in Stage IIIB ALK-positive NSCLC combined with uniportal VATS. | J Cardiothorac Surg | 2026 | https://conductscience.org/library/papers/42366402 | PubMed |
| 42365360 | Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study. | J Pharm Health Care Sci | 2026 | https://conductscience.org/library/papers/42365360 | PubMed |
| 42361687 | S100A10 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating JUND/TNC axis-mediated EMT. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42361687 | PubMed |
| 42321727 | Body composition radiomics integrated with machine learning to predict prognosis in advanced NSCLC treated with first-line immunochemotherapy and concurrent radiotherapy. | BMC Pulm Med | 2026 | https://conductscience.org/library/papers/42321727 | PubMed |
| 42318455 | Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database. | Front Oncol | 2026 | https://conductscience.org/library/papers/42318455 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37985191
GET https://conductscience.org/api/papers/v1/37985191/references?page=2